Acticor Biotech’s IPO

McDermott has advised Acticor Biotech on the offering. Acticor Biotech, a clinical stage biopharmaceutical company dedicated to developing a drug for the treatment of cardiovascular emergencies,...

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here